[{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"37f9a1df-a306-4aaa-b1f0-111ca2107f32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04835805","created_at":"2021-04-08T13:52:36.101Z","updated_at":"2024-07-02T16:35:03.372Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.","source_id_and_acronym":"NCT04835805","lead_sponsor":"Genentech, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/13/2021","start_date":" 05/13/2021","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 11/28/2025","study_completion_date":" 11/28/2025","last_update_posted":"2024-05-16"},{"id":"6eb97f2c-ec9d-435c-8cbb-be3b4fce8c70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284502","created_at":"2021-01-18T16:13:34.748Z","updated_at":"2024-07-02T16:35:41.554Z","phase":"Phase 1","brief_title":"HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03284502","lead_sponsor":"Hanmi Pharmaceutical Company Limited","biomarkers":" KRAS • BRAF • NRAS • PI3K","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13","tags":["KRAS • BRAF • NRAS • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-01"},{"id":"1802933f-fbab-49c2-b49b-c47cc4b1303d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03118817","created_at":"2021-01-18T15:21:55.497Z","updated_at":"2024-07-02T16:36:42.195Z","phase":"Phase 1","brief_title":"Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers","source_id_and_acronym":"NCT03118817","lead_sponsor":"Hanmi Pharmaceutical Company Limited","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e belvarafenib (RG6185)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/19/2017","start_date":" 05/19/2017","primary_txt":" Primary completion: 02/04/2020","primary_completion_date":" 02/04/2020","study_txt":" Completion: 02/04/2020","study_completion_date":" 02/04/2020","last_update_posted":"2020-08-10"}]